COV-BOOST is a blinded, multicentre, randomised, controlled, phase 2 trial investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of either the Oxford AstraZeneca or Pfizer-BioNTech vaccine in the UK.
The results were published in the Lancet at 23:30 UK time on Thursday 2 November 2021.
Journalists dialled in to this briefing to hear about the results from the scientists leading the trial, and to ask any questions.
Prof Saul Faust, COV-BOOST Chief Investigator and NISEC co-investigator, and Director of NIHR Southampton Clinical Research Facility and Professor of Paediatric Immunology and Infectious Diseases at the University of Southampton
Prof Matthew Snape, Chair of the National Vaccine Evaluation Consortium (NISEC), and Associate Professor in Paediatrics and Vaccinology at the University of Oxford
This Briefing was accompanied by an SMC Roundup of Comments.